KRAS and glioblastoma: Intriguingly, SETD4 expression correlated negatively with malignancy and immune‐related pathways including KRAS signaling, immune response, and IL2/STAT5 signaling pathways in BLCA, CHOL, and GBM, and positively in UVM.